Lista de obras - Alessio Aghemo - Dominio Público Uruguay

A 13-day, interferon-free regimen for chronic hepatitis C genotype 1 patients: between fear and hope

artículo científico publicado en 2011

A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis

artículo científico publicado en 2012

A review of the treatment of chronic hepatitis C virus infection in cirrhosis

artículo científico publicado en 2010

Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review.

artículo científico publicado en 2013

Allelic inhibition of displacement activity: a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms.

artículo científico publicado en 2012

Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management

artículo científico

Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense.

artículo científico publicado en 2012

Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients ⬇️

artículo científico publicado el 9 de julio de 2013

Cirrhosis regression in chronic hepatitis C: an old tale with a new ending

artículo científico publicado en 2009

Clinical drivers in naïve patient eligibility for treatment of chronic hepatitis C.

artículo científico publicado en 2012

Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection

artículo científico publicado en 2014

Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C ⬇️

artículo científico publicado el 1 de septiembre de 2013

Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C ⬇️

artículo científico publicado el 1 de enero de 2012

Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis

artículo científico publicado en 2012

De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).

artículo científico

Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method

artículo científico publicado en 2010

Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: the importance of tumor cell differentiation.

artículo científico publicado en 2010

Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials.

artículo científico

Do gamma-glutamyltransferase levels identify HCV patients who require lifelong post-SVR follow-up?

artículo científico publicado en 2020

Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?

artículo científico publicado en 2011

Editorial: should we abandon HCV genotype testing? Maybe.

artículo científico publicado en 2019

Eukaryotic initiation factor 5B: a new player for the anti-hepatitis C virus effect of ribavirin?

artículo científico publicado en 2012

Feasibility and reproducibility of spleen transient elastography and its role in combination with liver transient elastography for predicting the severity of chronic viral hepatitis

artículo científico publicado en 2013

Gastrointestinal involvement attenuates COVID-19 severity and mortality

scientific article published on 09 September 2020

Genetic variation in interleukin-28B predicts hepatitis C treatment-induced viral clearance in genotype 1 patients: the dawn of a new era?

artículo científico publicado en 2010

Genetic variation in the interleukin -28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection

article

HBV and HCV therapy.

artículo científico publicado en 2009

HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C.

artículo científico publicado en 2009

HCV screening: Moving from theory to practice

artículo científico publicado en 2020

Hepatitis C genotype 3: a tough match for interferon-free regimens

artículo científico publicado en 2014

Hepatitis C treatment in patients with kidney disease.

artículo científico

Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy.

artículo científico publicado en 2009

Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside.

artículo científico

Hepatorenal syndrome and novel advances in its management

artículo científico

High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma

artículo científico publicado en 2018

High levels of factor VIII and risk of extra-hepatic portal vein obstruction

artículo científico publicado en 2009

How to optimize HCV therapy in genotype 2 patients ⬇️

artículo científico publicado el 1 de febrero de 2013

Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis

artículo científico publicado en 2011

Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation

artículo científico publicado en 2013

Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin

artículo científico publicado en 2012

Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies

artículo científico publicado en 2013

Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.

artículo científico publicado en 2013

Insulin resistance and response to telaprevir plus pegylated interferon and ribavirin: a requiem for the HOMA score?

artículo científico publicado en 2012

Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients

artículo científico publicado en 2012

Interferon in the treatment of chronic hepatitis C: a drug caught between past and future.

artículo científico publicado en 2011

Interferon-free oral therapy for hepatitis C: "faraway, so close!"

scientific article published on 19 March 2012

Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.

artículo científico publicado en 2012

Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics?

artículo científico publicado en 2008

Is there need for more than one IL28B single nucleotide polymorphism in hepatitis C clinical practice?

scientific article published on 01 January 2013

Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis

artículo científico publicado en 2008

Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV-1 null responders

artículo científico publicado en 2013

Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection

artículo científico publicado en 2013

New horizons in hepatitis C antiviral therapy with direct-acting antivirals.

artículo científico

Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C

artículo científico publicado en 2011

PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.

artículo científico publicado en 2013

Peginterferon Alfa-2B versus peginterferon Alfa-2A with ribavirin for the treatment of chronic hepatitis C: the pursuit of an ideal

artículo científico publicado en 2009

Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: the plot thickens

artículo científico publicado en 2011

Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.

artículo científico publicado en 2009

Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C.

scientific article published on 20 July 2010

Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement the INRliver for the calculation of the MELD score

artículo científico publicado en 2009

Post-liver transplantation graft biopsies should not be used to assess the IL28B donor genotype in HCV recipients

artículo científico publicado en 2012

Postsustained Virological Response Management in Hepatitis C Patients

artículo científico publicado en 2020

Predictors of psychopathological outcome during peg-interferon and ribavirin therapy in patients with chronic HCV-correlated hepatitis.

artículo científico publicado en 2012

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.

artículo científico publicado en 2009

Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism

artículo científico publicado en 2007

Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients.

artículo científico publicado en 2011

Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients

artículo científico publicado en 2013

Sarcopenia in chronic liver disease: easy to diagnose but hard to treat

artículo científico publicado en 2020

Selection of resistant-associated variants to the NS5A inhibitor daclatasvir: revenge of the hepatitis C virus

artículo científico publicado en 2013

Should Artificial Intelligence‐based language models be allowed in developing scientific manuscripts? A debate between <scp>ChatGPT</scp> and the editors of <i>Liver International</i>

artículo científico publicado en 2023

Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.

artículo científico publicado en 2012

Telaprevir for hepatitis C re-treatment: an open door on a long and winding road

scientific article published on 21 August 2010

The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.

artículo científico publicado en 2006

The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy.

artículo científico publicado en 2011

The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin

artículo científico publicado en 2009

The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response.

artículo científico publicado en 2013

The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: should we utilize more?

artículo científico publicado en 2009

The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis

artículo científico publicado en 2007

Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma

artículo científico publicado en 2011

Treatment of chronic hepatitis C with pegylated interferon-α in a patient with recurrent autoimmune thrombotic thrombocytopenic purpura.

artículo científico publicado en 2012

Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir.

artículo científico publicado en 2012

Treatment of nonresponder patients with chronic hepatitis C: to repeat or not to repeat? That is the question

scientific article published on 28 August 2009

Treatment of patients with HCV related cirrhosis: many rewards with very few risks.

artículo científico publicado en 2012

Treatment of patients with dual hepatitis B and C: a step in the right direction

artículo científico publicado en 2013

Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF)

artículo científico publicado en 2014

Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy.

artículo científico publicado en 2010

US features of liver surface nodularity as a predictor of severe fibrosis in chronic hepatitis C

artículo científico publicado en 2005

Understanding the Role of PNPLA3 Genetic Variants in Patients with Chronic Hepatitis C Infection ⬇️

artículo científico publicado el 27 de junio de 2012

Vasculitis changes in COVID-19 survivors with persistent symptoms: an [18F]FDG-PET/CT study

artículo científico publicado en 2020

Lista de obras de Alessio Aghemo

A 13-day, interferon-free regimen for chronic hepatitis C genotype 1 patients: between fear and hope

A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis

A review of the treatment of chronic hepatitis C virus infection in cirrhosis

Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review.

Allelic inhibition of displacement activity: a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms.

Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management

Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense.

Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients ⬇️

Cirrhosis regression in chronic hepatitis C: an old tale with a new ending

Clinical drivers in naïve patient eligibility for treatment of chronic hepatitis C.

Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection

Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C ⬇️

Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C ⬇️

Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis

De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).

Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method

Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: the importance of tumor cell differentiation.

Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials.

Do gamma-glutamyltransferase levels identify HCV patients who require lifelong post-SVR follow-up?

Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?

Editorial: should we abandon HCV genotype testing? Maybe.

Eukaryotic initiation factor 5B: a new player for the anti-hepatitis C virus effect of ribavirin?

Feasibility and reproducibility of spleen transient elastography and its role in combination with liver transient elastography for predicting the severity of chronic viral hepatitis

Gastrointestinal involvement attenuates COVID-19 severity and mortality

Genetic variation in interleukin-28B predicts hepatitis C treatment-induced viral clearance in genotype 1 patients: the dawn of a new era?

Genetic variation in the interleukin -28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection

HBV and HCV therapy.

HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C.

HCV screening: Moving from theory to practice

Hepatitis C genotype 3: a tough match for interferon-free regimens

Hepatitis C treatment in patients with kidney disease.

Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy.

Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside.

Hepatorenal syndrome and novel advances in its management

High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma

High levels of factor VIII and risk of extra-hepatic portal vein obstruction

How to optimize HCV therapy in genotype 2 patients ⬇️

Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis

Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation

Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin

Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies

Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.

Insulin resistance and response to telaprevir plus pegylated interferon and ribavirin: a requiem for the HOMA score?

Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients

Interferon in the treatment of chronic hepatitis C: a drug caught between past and future.

Interferon-free oral therapy for hepatitis C: "faraway, so close!"

Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.

Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics?

Is there need for more than one IL28B single nucleotide polymorphism in hepatitis C clinical practice?

Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis

Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV-1 null responders

Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection

New horizons in hepatitis C antiviral therapy with direct-acting antivirals.

Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C

PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.

Peginterferon Alfa-2B versus peginterferon Alfa-2A with ribavirin for the treatment of chronic hepatitis C: the pursuit of an ideal

Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: the plot thickens

Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.

Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C.

Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement the INRliver for the calculation of the MELD score

Post-liver transplantation graft biopsies should not be used to assess the IL28B donor genotype in HCV recipients

Postsustained Virological Response Management in Hepatitis C Patients

Predictors of psychopathological outcome during peg-interferon and ribavirin therapy in patients with chronic HCV-correlated hepatitis.

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.

Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism

Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients.

Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients

Sarcopenia in chronic liver disease: easy to diagnose but hard to treat

Selection of resistant-associated variants to the NS5A inhibitor daclatasvir: revenge of the hepatitis C virus

Should Artificial Intelligence‐based language models be allowed in developing scientific manuscripts? A debate between <scp>ChatGPT</scp> and the editors of <i>Liver International</i>

Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.

Telaprevir for hepatitis C re-treatment: an open door on a long and winding road

The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.

The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy.

The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin

The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response.

The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: should we utilize more?

The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis

Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma